These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 29207968)

  • 21. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review.
    Hohla F; Hopfinger G; Romeder F; Rinnerthaler G; Bezan A; Stättner S; Hauser-Kronberger C; Ulmer H; Greil R
    Int J Oncol; 2014 Jan; 44(1):319-26. PubMed ID: 24247204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
    Ho MY; Kennecke HF; Renouf DJ; Cheung WY; Lim HJ; Gill S
    Am J Clin Oncol; 2017 Dec; 40(6):552-554. PubMed ID: 26165420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Different Treatment Modalities on the Outcome of Pancreatic Cancer.
    Khan M; Ashraf MI; Syed AA; Hanif F
    J Coll Physicians Surg Pak; 2017 Aug; 27(8):470-474. PubMed ID: 28903837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
    Popescu RA; Norman A; Ross PJ; Parikh B; Cunningham D
    J Clin Oncol; 1999 Aug; 17(8):2412-8. PubMed ID: 10561304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: a Population-based Study.
    Karim S; Zhang-Salomans J; Biagi JJ; Asmis T; Booth CM
    Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e16-e21. PubMed ID: 29137884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancer.
    Burtness B; Thomas L; Sipples R; McGurk M; Salikooti S; Christoforou M; Mirto G; Salem R; Sosa J; Kloss R; Rahman Z; Chung G; Lacy J; Murren JR
    Cancer J; 2007; 13(4):257-62. PubMed ID: 17762761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma.
    Sadot E; Doussot A; O'Reilly EM; Lowery MA; Goodman KA; Do RK; Tang LH; Gönen M; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Allen PJ
    Ann Surg Oncol; 2015 Oct; 22(11):3512-21. PubMed ID: 26065868
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
    Sylvie L; Silvia S; Salah-Eddin AB; Markus F; Florian L; Peter TP; Bernhard H; Martin A; Alexander N
    Eur J Cancer; 2015 Sep; 51(14):1918-26. PubMed ID: 26216588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].
    Kiba T; Saito Y; Otomo C; Sato M; Meguro T
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):913-5. PubMed ID: 27431641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity.
    Lee JC; Kim JW; Ahn S; Kim HW; Lee J; Kim YH; Paik KH; Kim J; Hwang JH
    Eur J Cancer; 2017 May; 76():125-133. PubMed ID: 28324747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Very Early Onset Pancreatic Adenocarcinoma - Clinical Presentation, Risk Factors and Therapeutic Options.
    Bunduc Ș; Iacob R; Costache R; Stoica B; Radu C; Gheorghe C
    Chirurgia (Bucur); 2018; 113(3):405-411. PubMed ID: 29981672
    [No Abstract]   [Full Text] [Related]  

  • 33. Current treatment landscape and emerging therapies for pancreatic cancer.
    Adel N
    Am J Manag Care; 2019 Jan; 25(1 Suppl):S3-S10. PubMed ID: 30681819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic advances in pancreatic cancer: miles to go before we sleep.
    Bekaii-Saab T; Goldberg R
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638250
    [No Abstract]   [Full Text] [Related]  

  • 35. Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
    Sasaki Y; Hamada K; Kaneta T; Takahashi T; Kubota Y; Ishida H; Ichikawa W
    Cancer Sci; 2015 Aug; 106(8):1100. PubMed ID: 26268893
    [No Abstract]   [Full Text] [Related]  

  • 36. [Palliative chemotherapy for pancreatic cancer].
    Buscail L; Bournet B; Guimbaud R
    Gastroenterol Clin Biol; 2006 Jan; 30(1):106-9. PubMed ID: 16514388
    [No Abstract]   [Full Text] [Related]  

  • 37. Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
    Okusaka T; Ikeda M; Fukutomi A; Ioka T; Furuse J; Ohkawa S; Isayama H; Boku N
    Cancer Sci; 2015 Aug; 106(8):1101-2. PubMed ID: 26268894
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of Patients with Advanced Gastroesophageal Adenocarcinoma: Does Age Matter?
    Lorenzen S; Hofheinz RD
    Drugs Aging; 2019 May; 36(5):403-409. PubMed ID: 30680677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Intensity, not Age, Affects Survival Time of Patients with Advanced Pancreatic Cancer.
    Kunkel J; Bohle W; Henseling S; Zoller W
    J Gastrointestin Liver Dis; 2021 Sep; 30(3):380-387. PubMed ID: 34375378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma.
    de Jesus VHF; Camandaroba MPG; Donadio MDS; Cabral A; Muniz TP; de Moura Leite L; Sant'Ana LF
    J Gastrointest Oncol; 2018 Aug; 9(4):694-707. PubMed ID: 30151266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.